Rifampicin and Thiacetazone Treatment Regimens in HIV Infected Tuberculosis Patients

WHO estimates that more than 5.6 million persons worlswide are dually infected with HIV and M.tuberculosis. HIV confers the greatest known risk for the development of active TB; by reactivating dormant infection; but progressive primary infection. Prior to HIV pandemic; thiatazone was widely used in Tb treatment in developing countries due to its low cost and availability in a combination formulation with isoniazid (INH). In conclusion; the result showed that the rate of adverse drug reactions in the STH arm was more than 12 times higher than in the RHZ arm. Sputum conversion was more rapid in patients treated with RHZ. RHZ is recommended for treatment of tuberculosis in HIV infected persons